BEL114424: A Phase 2 Pilot, Single Centre, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in the Prevention of Allograft Rejection in Adult Subjects After Renal Transplantation.

Next Previous
Trial Profile

BEL114424: A Phase 2 Pilot, Single Centre, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in the Prevention of Allograft Rejection in Adult Subjects After Renal Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Belimumab (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 27 Sep 2017 Results of a post-hoc analysis presented at the 18th Congress of the European Society for Organ Transplantation
    • 03 May 2017 Results assessing safety and efficacy and post hoc whole blood gene expression analysis, presented at the 2017 American Transplant Congress
    • 18 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top